Dezhong Wen1, Ping Qiao2, Li Wang3. 1. Institute of Genetics and Cytology, Northeast Normal University; School of Life Science, Northeast Normal University, Changchun 130024, China; Department of Genetics, School of Basic Medical Sciences, Jilin University, Changchun 130021, China. 2. Department of Pharmacology, School of Basic Medical Sciences, Jilin University, Changchun 130021, China. 3. Institute of Genetics and Cytology, Northeast Normal University; School of Life Science, Northeast Normal University, Changchun 130024, China. Electronic address: wangli@nenu.edu.cn.
Abstract
BACKGROUND AND AIMS: Obesity is a serious health problem that is implicated in many metabolic disorders. Recent studies have proposed that microRNA-223 (miR-223) is a potent regulator of many diseases related to obesity. However, the association of miR-223 with obesity remains unclear. In this study, we examined the relationship between serum miR-223 and obesity. DESIGN: A total of 121 subjects were selected, including 41 normal-weight, 40 overweight and 40 obesity subjects. The overweight and obesity subjects received lifestyle intervention for 3 months after baseline examination. Quantitative real-time PCR was used to measure the expression of circulating miR-223 in the serum. RESULTS: MiR-223 was lower in both overweight and obesity subjects compared with normal-weight control (1.06 vs. 7.54, p<0.001; 4.56 vs. 7.54, p<0.001, respectively). Circulating miR-223 increased significantly in both overweight and obesity groups after lifestyle intervention. Furthermore, subjects with the lowest tertile of miR-223 expression had the highest obesity prevalence. The odds ratio was 2.77 (95% confidence interval: 1.59-6.54, p<0.05) compared with the highest tertile of miR-223 expression. Such association was still apparent after adjusting for other major risk factors. CONCLUSION: The findings in this study suggest that miR-223 is a factor of obesity. The level of miR-223 in the serum can be used as a biomarker of obesity and therapeutic response.
BACKGROUND AND AIMS: Obesity is a serious health problem that is implicated in many metabolic disorders. Recent studies have proposed that microRNA-223 (miR-223) is a potent regulator of many diseases related to obesity. However, the association of miR-223 with obesity remains unclear. In this study, we examined the relationship between serum miR-223 and obesity. DESIGN: A total of 121 subjects were selected, including 41 normal-weight, 40 overweight and 40 obesity subjects. The overweight and obesity subjects received lifestyle intervention for 3 months after baseline examination. Quantitative real-time PCR was used to measure the expression of circulating miR-223 in the serum. RESULTS:MiR-223 was lower in both overweight and obesity subjects compared with normal-weight control (1.06 vs. 7.54, p<0.001; 4.56 vs. 7.54, p<0.001, respectively). Circulating miR-223 increased significantly in both overweight and obesity groups after lifestyle intervention. Furthermore, subjects with the lowest tertile of miR-223 expression had the highest obesity prevalence. The odds ratio was 2.77 (95% confidence interval: 1.59-6.54, p<0.05) compared with the highest tertile of miR-223 expression. Such association was still apparent after adjusting for other major risk factors. CONCLUSION: The findings in this study suggest that miR-223 is a factor of obesity. The level of miR-223 in the serum can be used as a biomarker of obesity and therapeutic response.
Authors: Marcelo A Mori; Raissa G Ludwig; Ruben Garcia-Martin; Bruna B Brandão; C Ronald Kahn Journal: Cell Metab Date: 2019-08-22 Impact factor: 27.287
Authors: M Parrizas; X Mundet; C Castaño; S Canivell; X Cos; L Brugnara; C Giráldez-García; E Regidor; M Mata-Cases; J Franch-Nadal; A Novials Journal: J Endocrinol Invest Date: 2019-11-12 Impact factor: 5.467
Authors: Evelyn B Parr; Donny M Camera; Louise M Burke; Stuart M Phillips; Vernon G Coffey; John A Hawley Journal: PLoS One Date: 2016-04-21 Impact factor: 3.240